8-K: Beyond Air Secures $32M Financing, Extends Cash Runway

Beyond Air, Inc. announced new financing agreements totaling up to $32 million, including a $12 million secured promissory note and a $20 million equity line of credit, extending its cash runway into 2027.

Summary

• Beyond Air, Inc. secured up to $32 million in potential financing through agreements with Streeterville Capital, LLC.
• This includes a $12 million secured promissory note with a 15% annual interest rate, maturing in 24 months, with no payments due for the first 12 months.
• A $20 million Equity Line of Credit (ELOC) provides the company the right, but not the obligation, to sell common stock to Streeterville Capital over a 24-month period.
• The company's proforma cash, cash equivalents, restricted cash, and marketable securities stood at $22.9 million as of September 30, 2025, incorporating the $12 million from the promissory note.
• The financing is expected to extend the company's cash runway into calendar year 2027.
• The Board approved a one-time stock option repricing for 726,618 options, reducing the exercise price to $1.95 per share for options previously priced above this amount.
• Existing lenders, including CEO Steven Lisi and Director Robert Carey, provided an additional $2 million term loan and received new five-year warrants for 512,821 shares at $1.95/share.
• In exchange for consenting to the new $12.05 million note, the exercise price of 2024 warrants held by Mr. Lisi and Mr. Carey (757,975 shares) was reduced to $1.95/share.

Sentiment

Score: 3

Explanation: While the company secured significant financing, the terms of the debt (high interest, restrictive covenants, trigger events) and the necessity of a large-scale option repricing suggest underlying financial challenges and a high cost of capital. The cash infusion provides a lifeline and extends runway, but the overall structure points to a difficult financial position rather than a strong growth trajectory.

Positives

• Secured up to $32 million in potential financing, providing a significant cash infusion.
• Extended cash runway into calendar 2027, offering greater financial stability.
• Management believes the financing positions the company to potentially achieve profitability, especially with the anticipated launch of a second-generation LungFit PH system.
• The Equity Line of Credit (ELOC) provides flexibility as the company has the right, but not the obligation, to draw funds.
• The option repricing aims to align employee and stockholder interests and improve retention of key talent.

Negatives

• The $12 million promissory note carries a high annual interest rate of 15%.
• A guaranteed interest charge of $1,800,000 is due even if the note is repaid early within the first 12 months.
• A one-time monitoring fee is added to the outstanding balance if the note is outstanding on the 90-day anniversary, calculated as (Outstanding Balance / 0.85 Outstanding Balance), which can be substantial.
• Restrictive covenants prevent the company from issuing new debt or certain variable rate transactions while the note is outstanding without lender consent.
• Trigger Events and Events of Default provisions in the note allow the lender to increase the outstanding balance by 4-9% (up to three times each) for each occurrence and accelerate the note, indicating a high-risk financing structure.
• A significant portion ($6 million) of the $12 million note proceeds is placed in a restricted cash collateral account, limiting immediate liquidity.
• The repricing of options, while aimed at retention, could be viewed negatively by shareholders if the original exercise prices were significantly higher than the new $1.95 price, indicating a loss of value for existing options.
• The issuance of new warrants and repricing of existing warrants to insiders (CEO, Director) could raise corporate governance concerns regarding potential dilution and preferential treatment.

Risks

• Ability to raise additional capital in the future.
• Timing and results of future pre-clinical studies and clinical trials.
• Potential for regulatory authorities (FDA, non-U.S.) to delay or not grant approval for product candidates.
• The unproven nature of the approach to discover and develop novel drugs, which may not lead to efficacious or marketable products.
• Ability to fund further pre-clinical studies and clinical trials.
• Obtaining, maintaining, and protecting intellectual property.
• Competition from others using similar technology or developing products for similar uses.
• Dependence on collaborators.
• The company's stock price could fall below the Nasdaq Minimum Price, impacting the terms of the ELOC.
• Failure to maintain an effective registration statement for the resale of shares under the ELOC could trigger early redemption rights for the promissory note.
• The company's market capitalization falling below $50 million or 200-day median trading volume below $1 million could affect the monitoring fee credit.
• Trigger Events and Events of Default under the promissory note could lead to accelerated repayment obligations and increased interest rates.
• The company's ability to comply with Nasdaq's 19.99% limitation on equity issuances without shareholder approval.

Future Outlook

The company anticipates accelerating commercial expansion for LungFit PH and launching a second-generation LungFit PH system prior to the end of calendar 2026. Management believes this financing positions the company to potentially achieve profitability. The cash runway is extended into calendar 2027.

Management Comments

• "This strategic cash infusion provides flexibility to accelerate our commercial expansion, aimed at driving sales growth for LungFit PH."
• "Based on current projections for LungFit PH global revenues and the anticipated launch of our second generation LungFit PH prior to the end of calendar 2026, we believe this financing positions us to potentially achieve profitability."

Industry Context

The biopharmaceutical and medical device industry often requires significant capital for R&D, clinical trials, regulatory approvals, and commercialization. Companies frequently utilize a mix of debt and equity financing to fund operations and growth. The high interest rate on the promissory note and the structure of the equity line of credit suggest that traditional, less dilutive financing options might have been limited, which is not uncommon for development-stage or smaller commercial-stage companies in this sector. The focus on LungFit PH and pipeline development aligns with the typical growth strategies in the medical device space.

Comparison to Industry Standards

• The 15% annual interest rate on the secured promissory note is significantly higher than typical corporate debt for established, profitable companies, indicating a higher risk profile or limited access to conventional financing. For early-stage or high-growth biopharma companies, such rates can be seen in venture debt or distressed financing scenarios.
• The Equity Line of Credit (ELOC) with a 96% of VWAP purchase price (and 85% of Nasdaq Minimum Price for investor-initiated puts) is a common, albeit often dilutive, financing mechanism for smaller public companies, similar to "at-the-market" (ATM) offerings but with a fixed counterparty and a discount.
• The option repricing to $1.95 for options previously priced up to $10.80 is a substantial reduction, often seen in companies whose stock price has significantly declined, aiming to restore incentive value for employees and management. This is a common practice in struggling companies but can be controversial for shareholders.
• The issuance of new warrants and repricing of existing warrants to insiders (CEO, Director) is a related party transaction that, while potentially aligning interests, often warrants scrutiny for fairness and potential dilution compared to arms-length transactions.

Corporate Governance

Related Party Transactions

• Existing lenders, including CEO Steven Lisi and Director Robert Carey, provided an additional $2,000,000 term loan to the company.
• New five-year warrants to purchase up to 512,821 shares of common stock at an exercise price of $1.95 per share were issued to Director Robert Carey.
• The exercise price of the 2024 Warrants (757,975 shares) held by CEO Steven Lisi and Director Robert Carey was reduced to $1.95 per share.
• The repricing of 726,618 stock options included options held by CEO Steven Lisi, Director Robert Carey, Director Erick Lucera, Director Yoori Lee, Director Bill Forbes, CFO Douglas Larson, and COO Mike Gaul.

Stakeholder Impact

• Shareholders: Potential for significant dilution from the Equity Line of Credit. The option repricing, while intended to motivate management, could be viewed negatively as it effectively re-grants value at a lower price, potentially at the expense of existing shareholders. The high cost of debt will impact future earnings.
• Employees/Management: The option repricing is intended to improve retention and align interests, providing renewed incentive for those holding underwater options.
• Creditors: Streeterville Capital benefits from a high-interest, secured note with strong covenants and collateral. Existing lenders (including insiders) also benefit from an additional loan and repriced warrants.
• Customers: The financing is intended to accelerate commercial expansion of LungFit PH, potentially leading to broader availability of the product.

Next Steps

• File a registration statement by November 24, 2025, covering the resale of shares under the Equity Purchase Agreement.
• Accelerate commercial expansion for LungFit PH.
• Launch a second-generation LungFit PH system prior to the end of calendar 2026.
• Continue pre-clinical and clinical activities for other LungFit systems, autism spectrum disorder program, and Beyond Cancer, Ltd. initiatives.

Key Dates

Recommendation

The company has secured crucial financing that extends its cash runway and supports its commercial and development goals. This is a positive for operational continuity. However, the terms of the debt are expensive and restrictive, indicating a challenging financial environment. The significant option repricing and related party transactions, while aimed at aligning interests, could be viewed with caution by investors due to potential dilution and governance implications. Given the high-risk nature of biopharma development and commercialization, coupled with the costly financing, a 'hold' recommendation is appropriate. Investors should monitor execution of commercial expansion, progress in clinical trials, and the company's ability to manage its debt obligations and avoid trigger events. The long-term outlook depends heavily on successful product launches and market adoption, which remain speculative.

Keywords

Beyond Air, XAIR, Financing, Equity Line of Credit, Promissory Note, Secured Debt, Warrants, Option Repricing, Cash Runway, Medical Device, Biopharmaceutical, Nitric Oxide, LungFit PH, Streeterville Capital, Corporate Governance, SEC Filing, Capital Raise